Jenphar Bangladesh Limited is pleased to announce the successful launch of new oncology product Pazopanib Hydrochloride 400 mg tablet as the brand name of Zotrix 400 tablet.
Pazopanib Hydrochloride is an oral, potent, multi-targeted tyrosine kinase inhibitor. By Inhibiting the VEGFR-1, -2 & -3, PDGFR-α & -β, and c-Kit, it inhibits angiogenesis, tumor growth and proliferation.
By launching this product, Jenphar Bangladesh Limited has enriched its Oncology portfolio, offering the treatment options in Advanced Renal Cell Carcinoma & Advanced Soft Tissue Sarcoma which will serve in a better way to the mentioned cancer patients of the country & abroad.
Zotrix 400 mg Tab is available in a sealed HDPE container containing 14 Tablets.